These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31062171)

  • 1. 14-3-3/Tau Interaction and Tau Amyloidogenesis.
    Chen Y; Chen X; Yao Z; Shi Y; Xiong J; Zhou J; Su Z; Huang Y
    J Mol Neurosci; 2019 Aug; 68(4):620-630. PubMed ID: 31062171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloidogenesis of Tau protein.
    Nizynski B; Dzwolak W; Nieznanski K
    Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer's disease and the tauopathies.
    Ramachandran G; Udgaonkar JB
    Biochemistry; 2013 Jun; 52(24):4107-26. PubMed ID: 23721410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure and phase of tau: from monomer to amyloid filament.
    Zeng Y; Yang J; Zhang B; Gao M; Su Z; Huang Y
    Cell Mol Life Sci; 2021 Mar; 78(5):1873-1886. PubMed ID: 33078207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probable participation of 14-3-3 in tau protein oligomerization and aggregation.
    Sluchanko NN; Gusev NB
    J Alzheimers Dis; 2011; 27(3):467-76. PubMed ID: 21876254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated full-length Tau interacts with 14-3-3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14-3-3 dimer.
    Neves JF; Petrvalská O; Bosica F; Cantrelle FX; Merzougui H; O'Mahony G; Hanoulle X; Obšil T; Landrieu I
    FEBS J; 2021 Mar; 288(6):1918-1934. PubMed ID: 32979285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteins that mediate protein aggregation and cytotoxicity distinguish Alzheimer's hippocampus from normal controls.
    Ayyadevara S; Balasubramaniam M; Parcon PA; Barger SW; Griffin WS; Alla R; Tackett AJ; Mackintosh SG; Petricoin E; Zhou W; Shmookler Reis RJ
    Aging Cell; 2016 Oct; 15(5):924-39. PubMed ID: 27448508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau fibrillogenesis.
    Chaudhary N; Nagaraj R
    Subcell Biochem; 2012; 65():75-90. PubMed ID: 23225000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Polymerase δ-Interacting Protein 2 (PolDIP2) Inhibits the Formation of Human Tau Oligomers and Fibrils.
    Kasho K; Krasauskas L; Smirnovas V; Stojkovič G; Morozova-Roche LA; Wanrooij S
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
    Avila J
    FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design.
    Wang D; Huang X; Yan L; Zhou L; Yan C; Wu J; Su Z; Huang Y
    Protein J; 2021 Oct; 40(5):656-668. PubMed ID: 34401998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resonance Raman spectroscopic measurements delineate the structural changes that occur during tau fibril formation.
    Ramachandran G; Milán-Garcés EA; Udgaonkar JB; Puranik M
    Biochemistry; 2014 Oct; 53(41):6550-65. PubMed ID: 25284680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential interaction and aggregation of 3-repeat and 4-repeat tau isoforms with 14-3-3zeta protein.
    Sadik G; Tanaka T; Kato K; Yanagi K; Kudo T; Takeda M
    Biochem Biophys Res Commun; 2009 May; 383(1):37-41. PubMed ID: 19324008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease.
    Mi K; Johnson GV
    Curr Alzheimer Res; 2006 Dec; 3(5):449-63. PubMed ID: 17168644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSK3: a possible link between beta amyloid peptide and tau protein.
    Hernández F; Gómez de Barreda E; Fuster-Matanzo A; Lucas JJ; Avila J
    Exp Neurol; 2010 Jun; 223(2):322-5. PubMed ID: 19782073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
    Dickey CA; Petrucelli L
    Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation.
    Hasegawa M
    Biomolecules; 2016 Apr; 6(2):. PubMed ID: 27136595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational heterogeneity of tau: Implication on intrinsic disorder, acid stability and fibrillation in Alzheimer's disease.
    Jebarupa B; Muralidharan M; Arun A; Mandal AK; Mitra G
    Biophys Chem; 2018 Oct; 241():27-37. PubMed ID: 30081240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of 14-3-3 in tubulin instability and impaired axon development is mediated by Tau.
    Joo Y; Schumacher B; Landrieu I; Bartel M; Smet-Nocca C; Jang A; Choi HS; Jeon NL; Chang KA; Kim HS; Ottmann C; Suh YH
    FASEB J; 2015 Oct; 29(10):4133-44. PubMed ID: 26103986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.